Skip to main content
OpenTrials
Completed

NCT Number: NCT00116675

Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for four weeks.

A second purpose is to evaluate the safety of the drug.

Completed

Looking for future studies?

Notify Me

Key information

Age range

3 year–11 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Children's Clinic of Jonesboro, PA, Jonesboro, Arkansas, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of common warts
  • Ages between 3 to 11

Exclusion criteria

  • Other types of wart(s), ie. plantar
  • Currently participating in another clinical study
  • Chronic viral hepatitis B or C

Treatment and study plan

Resiquimod

Drug

Primary outcomes

  1. Clearance of treated wart(s)

Secondary outcomes

  1. Partial clearance of treated wart(s)

  2. Wart recurrence

Sponsors and collaborators

Lead sponsor

Graceway Pharmaceuticals, LLC

Industry

Registry information

Official study title

A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Pediatric Subjects

Important dates

Study start
2005
Study completion
2006
First posted
Jul 1, 2005
Registry last updated
Feb 19, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.